Spots Global Cancer Trial Database for receptor tyrosine kinase inhibitor
Every month we try and update this database with for receptor tyrosine kinase inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers | NCT01316822 | Metastatic Canc... | ARRY-382, cFMS ... | 18 Years - | Array BioPharma | |
A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers | NCT01316822 | Metastatic Canc... | ARRY-382, cFMS ... | 18 Years - | Array BioPharma | |
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer | NCT01496313 | Thyroid Cancer | 300mg vandetani... 150mg vandetani... | 18 Years - | Sanofi | |
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) | NCT04246177 | Carcinoma, Hepa... | Lenvatinib Pembrolizumab Oral Placebo IV Placebo TACE | 18 Years - | Merck Sharp & Dohme LLC | |
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) | NCT04305041 | Melanoma | Pembrolizumab Quavonlimab Vibostolimab Lenvatinib ATRA | 18 Years - 120 Years | Merck Sharp & Dohme LLC | |
Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) | NCT03713593 | Carcinoma, Hepa... | lenvatinib pembrolizumab saline placebo | 18 Years - | Merck Sharp & Dohme LLC |